Bill Warren advises clients on strategic intellectual property issues primarily in the life sciences sector, but also in a number of other industries. The majority of his practice focuses on patents related to biotechnology, medical device and pharmaceutical inventions. Bill prosecutes patents, counsels clients on patent validity and infringement issues and prepares product clearance opinions and development strategies. He also negotiates technology transfer licensing agreements and conducts intellectual property due diligence.
Bill is chair of the firm's biotechnology and life sciences team, and previously led Sutherland's Intellectual Property Practice Group. He also protects trademarks and copyrights and, when necessary, participates in litigating intellectual property issues. In particular, he counsels various entities on Hatch-Waxman generic pharmaceutical and related biosimilars issues. For more than two decades, Bill has worked with clients ranging from multinational corporations, to early-stage entrepreneurial companies, to nonprofit university and science research centers. He is a frequent speaker and writer on developments in patent law affecting the life sciences industry.
Conducted freedom-to-operate analyses for the commercialization of therapeutic recombinant proteins and monoclonal antibodies for a global specialty pharmaceutical company.
Completes diligence on the acquisition and licensing of bead-based molecular bioarray nucleic acid detection platform technology.
Advises a medical device company on patenting cardiovascular access and closure products.
Awards and Rankings
Selected for inclusion in IP Stars by Managing Intellectual Property (2013-2016)
Named among “Georgia's Legal Elite” by Georgia Trend magazine (2007)
Selected for inclusion in Georgia Super Lawyers “Rising Stars” (2005-2006)